Skip to main content

Table 1 Proportion of patient population receiving adjuvant chemotherapy by diagnosis time period and menopausal status

From: Cost-effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in women with early-stage estrogen- or progesterone-receptor-positive, axillary lymph-node negative breast cancer

Diagnosis time period

No. of women who diagnosed with ER + or PR + LN- ESBC

No. of women received adjuvant chemotherapy (%)

Pre-menopausal women

Post-menopausal women

Pre-menopausal women

2000-2002 vs. 2003-2005

Post-menopausal women

2000-2002 vs. 2003-2005

ρ value†

ρ value†

2000 − 2002

109

389

74 (69)

.88

73 (18.8)

.7

2003 − 2005

106

506

71 (67)

 

90 (17.7)

 
  1. † Chi-square test.